Viral suppression among middle-aged and aging MSM living with HIV: Partnership type and quality
- PMID: 34597316
- PMCID: PMC8486120
- DOI: 10.1371/journal.pone.0258032
Viral suppression among middle-aged and aging MSM living with HIV: Partnership type and quality
Abstract
Functional support-the availability of material aid, emotional support, or companionship-promotes general well-being. For men who have sex with men (MSM) living with HIV, having a person who supports you associates with viral suppression. This study examines the association between supportive partnerships and HIV viral suppression among middle-aged and aging MSM living with HIV. A total of 423 middle-aged and aging MSM (mean age, 58.2 years) from the Multicenter AIDS Cohort Study provided self-reported data about their partnerships. Separate Poisson regression models assessed how partnership type, support, strain, and duration from April 2017 were associated with repeated viral load measurements up to April 2019. Of the follow-up visits (N = 1289), 90.0% of participants were virally suppressed. Most participants reported being non-Hispanic White (61.0%) and college-educated (83.4%). Participants were asked about their primary partnerships (i.e., "someone they are committed to above anyone else") and secondary partnerships (i.e., those who can also be intimate or supportive but not necessarily romantic or sexual). The participants reported: no partnerships (45.2%), only primary partnerships (31.0%), only secondary partnerships (11.1%), or both primary and secondary partnerships (12.8%). Primary and secondary partnerships had mean (SD) durations of 15.9 (11.3) and 25.2 (16.5) years, respectively. Participants reporting both primary and secondary partnerships (compared with no partnership) showed significantly higher odds of being virally suppressed (adjusted prevalence ratio [aPR], 1.04; 95% CI, 1.00-1.08; p = 0.043). Albeit not statistically significant, primary-only (aPR, 1.01; 95% CI, 0.97-1.06; p = 0.547) or secondary-only (aPR, 1.03; 95% CI, 0.98-1.08; p = 0.224) partnership types were positively associated with viral suppression. Partner support and strain were not associated with viral suppression in any partnership group. Being older and non-Hispanic Black were positively and negatively associated with viral suppression, respectively. Encouraging partnerships should be considered one of clinicians' many tools to help middle-aged and aging MSM achieve long-term viral suppression.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
-
- HIV Undetectable = Untransmittable (U = U), or Treatment as Prevention. 2019 May 21. In: National Institute of Allergy and Infectious Diseases [Internet]. Available from https://www.niaid.nih.gov/diseases-conditions/treatment-prevention.
-
- Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al.; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–181. doi: 10.1001/jama.2016.5148 - DOI - PubMed
-
- Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al.; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet. 2018;5(8):e438–e447. doi: 10.1016/S2352-3018(18)30132-2 - DOI - PubMed
-
- Rodger AJ. Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: the PARTNER2 Study extended results in gay men. Presented at: 22nd International AIDS Conference; July 23–27, 2018; Amsterdam, the Netherlands.
-
- Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018. HIV Surveillance Supplemental Report. 2020 May. In: Centers for Disease Control and Prevention [Internet]. Available from http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
Publication types
MeSH terms
Grants and funding
- U01 HL146205/HL/NHLBI NIH HHS/United States
- U01 HL146208/HL/NHLBI NIH HHS/United States
- U01 HL146192/HL/NHLBI NIH HHS/United States
- U01 HL146242/HL/NHLBI NIH HHS/United States
- U01 HL146201/HL/NHLBI NIH HHS/United States
- U01 HL146193/HL/NHLBI NIH HHS/United States
- U01 HL146194/HL/NHLBI NIH HHS/United States
- U01 HL146241/HL/NHLBI NIH HHS/United States
- P30 AI027767/AI/NIAID NIH HHS/United States
- P30 AI050409/AI/NIAID NIH HHS/United States
- U01 HL146333/HL/NHLBI NIH HHS/United States
- R01 MD010680/MD/NIMHD NIH HHS/United States
- U01 HL146245/HL/NHLBI NIH HHS/United States
- U01 HL146204/HL/NHLBI NIH HHS/United States
- U01 HL146202/HL/NHLBI NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- U01 HL146240/HL/NHLBI NIH HHS/United States
- U01 HL146203/HL/NHLBI NIH HHS/United States
- P30 AI050410/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
